Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fedratinib plus CC-486 in Accelerated Phase Myelofibrosis
2021-003650-23Phase 2Active
- Sponsor
- Martin Luther University Halle-Wittenberg
- Start
- Feb 2022
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fedratinib and CC-486 in myeloproliferative disorder (MPD) and myelofibrosis (MF), sponsored by Martin Luther University Halle-Wittenberg. Primary endpoint: Safety and tolerability of fedratinib + CC-486 (Phase I). Started Feb 2022; status: active.
02
Drugs
fedratinibCC-486
03
Conditions
myeloproliferative disorder (MPD)myelofibrosis (MF)
Beyond the preview
Go deeper on 2021-003650-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003650-23.